| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
|
Nature
|
2006
|
27.91
|
|
2
|
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2007
|
12.62
|
|
3
|
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
|
Clin Cancer Res
|
2007
|
9.21
|
|
4
|
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
|
Cancer Res
|
2006
|
6.77
|
|
5
|
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.
|
Cancer Cell
|
2009
|
5.81
|
|
6
|
Making a tumour's bed: glioblastoma stem cells and the vascular niche.
|
Nat Rev Cancer
|
2007
|
4.54
|
|
7
|
Distinct requirements for Ras oncogenesis in human versus mouse cells.
|
Genes Dev
|
2002
|
4.30
|
|
8
|
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis.
|
J Clin Oncol
|
2008
|
3.84
|
|
9
|
Integrin alpha 6 regulates glioblastoma stem cells.
|
Cell Stem Cell
|
2010
|
3.82
|
|
10
|
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway.
|
Cancer Cell
|
2004
|
3.63
|
|
11
|
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.
|
Cell Cycle
|
2009
|
3.55
|
|
12
|
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.
|
Cell
|
2013
|
3.32
|
|
13
|
Notch promotes radioresistance of glioma stem cells.
|
Stem Cells
|
2010
|
3.07
|
|
14
|
Targeting cancer stem cells through L1CAM suppresses glioma growth.
|
Cancer Res
|
2008
|
2.97
|
|
15
|
Recent advances in the treatment of malignant astrocytoma.
|
J Clin Oncol
|
2006
|
2.55
|
|
16
|
HIF induces human embryonic stem cell markers in cancer cells.
|
Cancer Res
|
2011
|
2.46
|
|
17
|
c-Myc is required for maintenance of glioma cancer stem cells.
|
PLoS One
|
2008
|
2.41
|
|
18
|
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.
|
Cancer Cell
|
2013
|
2.38
|
|
19
|
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
|
J Clin Oncol
|
2008
|
2.32
|
|
20
|
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake.
|
Nat Neurosci
|
2013
|
2.30
|
|
21
|
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.
|
J Exp Med
|
2012
|
2.21
|
|
22
|
Phase II trial of temozolomide in patients with progressive low-grade glioma.
|
J Clin Oncol
|
2003
|
2.16
|
|
23
|
Brain cancer stem cells display preferential sensitivity to Akt inhibition.
|
Stem Cells
|
2008
|
2.12
|
|
24
|
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
|
Cancer Cell
|
2011
|
2.04
|
|
25
|
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.
|
Stem Cells
|
2009
|
1.97
|
|
26
|
Molecularly targeted therapy for malignant glioma.
|
Cancer
|
2007
|
1.96
|
|
27
|
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
|
J Clin Oncol
|
2005
|
1.85
|
|
28
|
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.
|
Cell
|
2011
|
1.77
|
|
29
|
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
|
Mol Carcinog
|
2007
|
1.74
|
|
30
|
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
|
Mol Cancer Ther
|
2005
|
1.66
|
|
31
|
Biology of glioma cancer stem cells.
|
Mol Cells
|
2009
|
1.64
|
|
32
|
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy.
|
Glia
|
2011
|
1.63
|
|
33
|
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
|
Clin Cancer Res
|
2006
|
1.63
|
|
34
|
Potential therapeutic implications of cancer stem cells in glioblastoma.
|
Biochem Pharmacol
|
2010
|
1.60
|
|
35
|
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
|
Neuro Oncol
|
2010
|
1.59
|
|
36
|
Informed consent in pediatric surgery: Do parents understand the risks?
|
Arch Otolaryngol Head Neck Surg
|
2010
|
1.55
|
|
37
|
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
|
J Clin Oncol
|
2009
|
1.53
|
|
38
|
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
|
J Clin Oncol
|
2002
|
1.50
|
|
39
|
Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells.
|
Nat Cell Biol
|
2011
|
1.49
|
|
40
|
Deadly teamwork: neural cancer stem cells and the tumor microenvironment.
|
Cell Stem Cell
|
2011
|
1.49
|
|
41
|
New treatment strategies for malignant gliomas.
|
Expert Rev Anticancer Ther
|
2006
|
1.47
|
|
42
|
Elevated invasive potential of glioblastoma stem cells.
|
Biochem Biophys Res Commun
|
2011
|
1.39
|
|
43
|
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
|
Clin Cancer Res
|
2008
|
1.35
|
|
44
|
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
|
Mol Cancer Ther
|
2004
|
1.35
|
|
45
|
Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways.
|
J Biol Chem
|
2009
|
1.33
|
|
46
|
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
|
Clin Cancer Res
|
2004
|
1.33
|
|
47
|
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
|
J Clin Oncol
|
2002
|
1.32
|
|
48
|
Hypoxia and hypoxia inducible factors in cancer stem cell maintenance.
|
Curr Top Microbiol Immunol
|
2010
|
1.32
|
|
49
|
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells.
|
PLoS One
|
2011
|
1.29
|
|
50
|
MET signaling regulates glioblastoma stem cells.
|
Cancer Res
|
2012
|
1.29
|
|
51
|
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
|
Cancer
|
2009
|
1.29
|
|
52
|
Designer therapies for glioblastoma multiforme.
|
Ann N Y Acad Sci
|
2008
|
1.28
|
|
53
|
Targeting A20 decreases glioma stem cell survival and tumor growth.
|
PLoS Biol
|
2010
|
1.27
|
|
54
|
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
|
J Neurooncol
|
2010
|
1.26
|
|
55
|
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A.
|
J Exp Med
|
2013
|
1.21
|
|
56
|
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
|
Cancer
|
2005
|
1.21
|
|
57
|
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness.
|
Cancer Res
|
2009
|
1.18
|
|
58
|
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.
|
Genes Dev
|
2012
|
1.15
|
|
59
|
Laminin alpha 2 enables glioblastoma stem cell growth.
|
Ann Neurol
|
2012
|
1.13
|
|
60
|
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
|
J Clin Oncol
|
2006
|
1.12
|
|
61
|
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1.
|
EMBO J
|
2011
|
1.10
|
|
62
|
Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity.
|
Cancer Res
|
2005
|
1.10
|
|
63
|
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
|
J Neurooncol
|
2007
|
1.10
|
|
64
|
Diagnosis and treatment of high-grade astrocytoma.
|
Neurol Clin
|
2007
|
1.08
|
|
65
|
β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma.
|
Cancer Res
|
2013
|
1.08
|
|
66
|
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
|
Cancer
|
2005
|
1.07
|
|
67
|
Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells.
|
Endocr Relat Cancer
|
2013
|
1.06
|
|
68
|
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.
|
Proc Natl Acad Sci U S A
|
2013
|
1.06
|
|
69
|
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells.
|
Stem Cells
|
2014
|
1.05
|
|
70
|
EGFR mutations and sensitivity to gefitinib.
|
N Engl J Med
|
2004
|
1.05
|
|
71
|
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.
|
J Biol Chem
|
2004
|
1.04
|
|
72
|
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.
|
Genes Cancer
|
2010
|
1.03
|
|
73
|
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
|
J Neurooncol
|
2011
|
1.02
|
|
74
|
The evolving landscape of glioblastoma stem cells.
|
Curr Opin Neurol
|
2013
|
1.02
|
|
75
|
The emerging role of anti-angiogenic therapy for malignant glioma.
|
Curr Treat Options Oncol
|
2008
|
1.01
|
|
76
|
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
|
Neuro Oncol
|
2008
|
0.99
|
|
77
|
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair.
|
Trends Neurosci
|
2012
|
0.99
|
|
78
|
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin.
|
Cancer Res
|
2013
|
0.99
|
|
79
|
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
|
Mol Cancer Ther
|
2007
|
0.98
|
|
80
|
New approaches to primary brain tumor treatment.
|
Anticancer Drugs
|
2006
|
0.96
|
|
81
|
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.
|
Neuro Oncol
|
2008
|
0.96
|
|
82
|
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
|
Drugs Today (Barc)
|
2006
|
0.96
|
|
83
|
Notch signaling in cancer stem cells.
|
Adv Exp Med Biol
|
2012
|
0.95
|
|
84
|
Squelching glioblastoma stem cells by targeting REST for proteasomal degradation.
|
Trends Neurosci
|
2009
|
0.95
|
|
85
|
NDRG4 is required for cell cycle progression and survival in glioblastoma cells.
|
J Biol Chem
|
2009
|
0.95
|
|
86
|
Chemotherapy and novel therapeutic approaches in malignant glioma.
|
Front Biosci
|
2005
|
0.95
|
|
87
|
Twisted tango: brain tumor neurovascular interactions.
|
Nat Neurosci
|
2011
|
0.95
|
|
88
|
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
|
Cancer Res
|
2006
|
0.95
|
|
89
|
Medical oncology: treatment and management of malignant gliomas.
|
Nat Rev Clin Oncol
|
2010
|
0.94
|
|
90
|
Glioma stem cell maintenance: the role of the microenvironment.
|
Curr Pharm Des
|
2011
|
0.93
|
|
91
|
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.
|
J Clin Invest
|
2014
|
0.93
|
|
92
|
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology?
|
Stem Cell Rev
|
2011
|
0.92
|
|
93
|
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
|
Neuro Oncol
|
2004
|
0.91
|
|
94
|
Improving the radiosensitivity of radioresistant and hypoxic glioblastoma.
|
Future Oncol
|
2010
|
0.91
|
|
95
|
Cancer stem cell-specific scavenger receptor 36 drives glioblastoma progression.
|
Stem Cells
|
2014
|
0.89
|
|
96
|
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
|
J Neurooncol
|
2012
|
0.89
|
|
97
|
Antiangiogenic therapy in malignant glioma: promise and challenge.
|
Curr Pharm Des
|
2007
|
0.88
|
|
98
|
Glioma development: where did it all go wrong?
|
Cell
|
2011
|
0.88
|
|
99
|
Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma.
|
Cancer Res
|
2012
|
0.88
|
|
100
|
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
|
Neuro Oncol
|
2009
|
0.87
|
|
101
|
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
|
Clin Cancer Res
|
2009
|
0.87
|
|
102
|
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
|
Neuro Oncol
|
2004
|
0.86
|
|
103
|
Aptamer identification of brain tumor-initiating cells.
|
Cancer Res
|
2013
|
0.86
|
|
104
|
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
|
Neuro Oncol
|
2006
|
0.85
|
|
105
|
Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.
|
PLoS One
|
2013
|
0.84
|
|
106
|
Decoding the cancer stem cell hypothesis in glioblastoma.
|
CNS Oncol
|
2013
|
0.82
|
|
107
|
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
|
J Neurooncol
|
2011
|
0.82
|
|
108
|
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
|
J Nucl Med
|
2006
|
0.82
|
|
109
|
Cadherin-11 regulates motility in normal cortical neural precursors and glioblastoma.
|
PLoS One
|
2013
|
0.82
|
|
110
|
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
|
Cancer
|
2012
|
0.81
|
|
111
|
Multiplex flow cytometry barcoding and antibody arrays identify surface antigen profiles of primary and metastatic colon cancer cell lines.
|
PLoS One
|
2013
|
0.81
|
|
112
|
Glioblastoma Stem Cells: A Neuropathologist's View.
|
J Oncol
|
2010
|
0.81
|
|
113
|
Bacterial flavohemoglobin: a molecular tool to probe mammalian nitric oxide biology.
|
Biotechniques
|
2011
|
0.81
|
|
114
|
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
|
Neuro Oncol
|
2008
|
0.80
|
|
115
|
Growth factor receptors define cancer hierarchies.
|
Cancer Cell
|
2013
|
0.78
|
|
116
|
Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.
|
Glia
|
2014
|
0.78
|
|
117
|
RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation.
|
J Clin Invest
|
2016
|
0.77
|
|
118
|
Looking in the miR-ror: TGF-β-mediated activation of NF-κB in glioma.
|
J Clin Invest
|
2012
|
0.77
|
|
119
|
Mitotic control of cancer stem cells.
|
Cancer Discov
|
2013
|
0.76
|
|
120
|
The quest for self-identity: not all cancer stem cells are the same.
|
Clin Cancer Res
|
2012
|
0.76
|
|
121
|
Molecular targeting of neural cancer stem cells: TTAGGG, you're it!
|
Clin Cancer Res
|
2011
|
0.76
|
|
122
|
TRP-ing up brain tumors.
|
Nat Med
|
2012
|
0.76
|
|
123
|
Malignant glioma drug discovery - targeting protein kinases.
|
Expert Opin Drug Discov
|
2007
|
0.75
|
|
124
|
Genomics informs glioblastoma biology.
|
Nat Genet
|
2013
|
0.75
|
|
125
|
Changing the fate of cancer, one splice at a time.
|
Proc Natl Acad Sci U S A
|
2013
|
0.75
|
|
126
|
Holding on to stemness.
|
Nat Cell Biol
|
2012
|
0.75
|
|
127
|
Nicotinamide metabolism regulates glioblastoma stem cell maintenance.
|
JCI Insight
|
2017
|
0.75
|
|
128
|
The cancer stem cell: a new therapeutic paradigm?
|
Expert Rev Anticancer Ther
|
2006
|
0.75
|
|
129
|
Molecularly targeted therapy in neuro-oncology.
|
Handb Clin Neurol
|
2012
|
0.75
|
|
130
|
Correction: Zika virus has oncolytic activity against glioblastoma stem cells.
|
J Exp Med
|
2017
|
0.75
|